Lonza primary, diseased primary and stem cells

Wednesday, 14 March, 2012 | Supplied by: Capsugel Australia Pty Ltd

Lonza primary, diseased primary and stem cells

Research shows that non-transformed, non-immortalised cells isolated directly from tissue provide conditions that closely simulate a living model and yield more physiologically significant results.

With Clonetics Primary Normal Cells and Media, Lonza provides over 150 authenticated primary human and animal cell types with optimised media for growth and maintenance.

With Clonetics Primary Diseased Cells, the company offers primary cells derived from patients with COPD, asthma, Type 1 and Type 2 diabetes.

The company’s Stem Cells and Media offer primary human adult stem and progenitor cells from bone marrow, cord blood and adipose tissue with growth and differentiation media, and ES-derived differentiated cells and media.

Lonza primary cells and media are tested together to guarantee performance. The company uses strict industry QC standards to ensure consistent performance on every lot manufactured.

All tissue utilised for the company’s human cell products is ethically obtained with documented and informed donor consent.

Online: lonzabioscience.com.au
Phone: 1300 657508
Related Products

Biosensis MAP2 antibodies

Biosensis's validated MAP2 antibodies are designed to help users identify MAP2, whether they...

Bio-Rad Laboratories Celselect Slides validated antibodies for rare cell and CTC enumeration

The antibodies are specific to CTC surface markers to enable the sensitive and specific...

Microbiologics UV-BioTAG QC microorganisms for quality control testing

UV-BioTAG, a line of reference strains containing green fluorescent protein (GFP) markers, makes...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd